Compare SXT & LQDA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | SXT | LQDA |
|---|---|---|
| Founded | 1882 | 2004 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Chemicals | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 5.5B | 5.5B |
| IPO Year | 1994 | 2020 |
| Metric | SXT | LQDA |
|---|---|---|
| Price | $132.00 | $42.69 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 5 | 8 |
| Target Price | ★ $144.40 | $54.38 |
| AVG Volume (30 Days) | 287.1K | ★ 4.8M |
| Earning Date | 10-30-2026 | 11-06-2026 |
| Dividend Yield | ★ 1.25% | N/A |
| EPS Growth | 7.48 | ★ 51.81 |
| EPS | ★ 2.24 | 1.26 |
| Revenue | ★ $1,396,499,000.00 | $158,320,000.00 |
| Revenue This Year | $11.85 | $357.27 |
| Revenue Next Year | $13.72 | $1.34 |
| P/E Ratio | $58.81 | ★ $31.31 |
| Revenue Growth | N/A | ★ 1031.18 |
| 52 Week Low | $82.60 | $22.05 |
| 52 Week High | $138.82 | $93.61 |
| Indicator | SXT | LQDA |
|---|---|---|
| Relative Strength Index (RSI) | 51.51 | 47.91 |
| Support Level | $131.37 | $35.00 |
| Resistance Level | $136.94 | $46.67 |
| Average True Range (ATR) | 3.23 | 2.90 |
| MACD | 0.01 | 2.32 |
| Stochastic Oscillator | 37.39 | 99.56 |
Sensient Technologies Corp manufactures and markets natural and synthetic colors, flavors, and other specialty ingredients. Sensient's offerings are predominantly applied to consumer-facing products, including food and beverage, cosmetics and pharmaceuticals, nutraceuticals, and personal care industries. Its principal products are flavors, flavor enhancers, ingredients, extracts, and bionutrients, essential oils, dehydrated vegetables and other food ingredients, natural and synthetic food and beverage colors, and others. The company's reportable segments are: Flavors & Extracts, which derive key revenue, Color, Asia Pacific, and Corporate and Other. Geographically, the company generates maximum revenue from North America, followed by Europe, Asia-Pacific, and other regions.
Liquidia Corp is a United States-based biopharmaceutical company focused on the development, manufacturing, and commercialization of products that address unmet patient needs, with the current focus directed towards the treatment of pulmonary hypertension (PH) and pulmonary hypertension associated with interstitial lung disease. It conducts research, development, and manufacturing of novel products by applying its proprietary PRINT technology, a particle engineering platform, to enable the precise production of uniform drug particles. Its product includes YUTREPIA (treprostinil) inhalation powder, for the treatment of pulmonary arterial hypertension. The company also conducting studies on L606, an investigational, liposomal formulation of treprostinil.